Halozyme Therapeutics (NASDAQ:HALO) Releases FY 2025 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 4.950-5.350 for the period, compared to the consensus EPS estimate of 5.050. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on HALO shares. Wells Fargo & Company lowered their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Piper Sandler boosted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. Benchmark restated a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, HC Wainwright lifted their target price on Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $62.78.

Halozyme Therapeutics Trading Up 2.5 %

NASDAQ HALO traded up $1.45 during trading hours on Friday, hitting $59.15. 1,235,596 shares of the company were exchanged, compared to its average volume of 1,290,993. The stock has a market cap of $7.28 billion, a PE ratio of 17.24, a price-to-earnings-growth ratio of 0.42 and a beta of 1.25. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The stock has a 50-day moving average price of $54.53 and a 200 day moving average price of $54.74. Halozyme Therapeutics has a 52 week low of $37.73 and a 52 week high of $65.53.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Analysts forecast that Halozyme Therapeutics will post 4.73 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now owns 38,611 shares of the company's stock, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the transaction, the senior vice president now directly owns 185,453 shares in the company, valued at $10,765,546.65. The trade was a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,697 shares of company stock valued at $1,461,001 in the last quarter. 2.40% of the stock is owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.